
|Articles|December 11, 2007
Orphan drug under study to be available to more patients
Gentium expands access to defibrotide under compassionate use basis
Advertisement
Gentium S.p.A has announced that it is expanding access to its investigational drug defibrotide for patients to treat severe veno-occlusive disease (VOD). The Villa Guardia, Italy, firm is taking this step because it has received "large numbers of requests" for the drug on a compassionate use basis. Gentium added that the expanded access will not affect the Phase III trial of the drug, since only patients who are not eligible to, or cannot, participate in the study can take advantage of the expanded access program. Defibrotide is an orphan drug that has been granted fast-track designation to treat severe VOD in stem cell transplant patients.
Advertisement
Related to this article

Infectious disease readiness depends on rehearsed workflows, bidirectional public health communication, and rapid access to care.

Pharmacist pain clinics typically focus on comprehensive medication management involving the entire patient scenario.

A case shows a suspected recurrence of pneumococcal disease that ended with removal of one cochlear implant and replacement of the other.

Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.

In celebration of the organizationās recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.

Local collaborations can turn pharmacies into care-coordination hubs, but lasting results require trained teams, shared data, and sustainable payment.

In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.
Advertisement
Advertisement
Trending on Drug Topics
1
From Binder to Action: Making Infectious Disease Outbreak Plans Operational
2
Retatrutide Delivers 20.8% Weight Loss in Adults With Type 2 Diabetes
3
Diabetes Medication Adherence Lags for Black and Hispanic Medicare Patients
4
FAQ: Policies for Pharmacists to Track Heading into 2026 Midterms
5

